COMP <GO>
EXEL vs NBIX // EV/EBITDA & P/E VALUATION
Exelixis Inc. (NASDAQ) VS. Neurocrine Biosciences Inc. (NASDAQ) • 15-METRIC TALLY: EXEL 9
— NBIX 2
▲ EV/EBITDA & P/E VALUATION LEADER: EXEL
LAST: $66.20 (-0.12%) • MKT CAP: $16.40B
valuation
18.4x
LAST: $146.38 (+0.58%) • MKT CAP: $14.88B
valuation
22.8x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EXEL VS. NBIX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EXEL | NBIX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 96.00% | 0.00 | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 35.10% | 15.70% | +19.40 | EXEL | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 18.4x | 22.8x | -4.40 | EXEL | /valuation <GO> |
| Free Cash Flow Yield | 5.34% | 5.03% | +0.31 | EXEL | /fcf-yield <GO> |
| Operating Margin | 37.60% | 21.60% | +16.00 | EXEL | /operating-margins <GO> |
| Net Profit Margin | 33.70% | 16.70% | +17.00 | EXEL | /net-margins <GO> |
| Revenue Growth (YoY) | 7.00% | 21.40% | -14.40 | NBIX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 16.64 | 8.13 | +8.51 | EXEL | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 9/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 63.3 | 56.1 | +7.20 | EXEL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.96 | 1.13 | -0.17 | NBIX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 19.5x | 26.1x | -6.60 | EXEL | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $16.40B | $14.88B | $1.52B | EXEL | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EXEL REV | NBIX REV | EXEL GROSS % | NBIX GROSS % | EXEL FCF | NBIX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.32B | $2.86B | 96.4% | 98.2% | $875.8M | $748.7M |
| FY 2024 | $2.17B | $2.36B | 96.5% | 98.6% | $671.5M | $557.2M |
| FY 2023 | $1.83B | $1.89B | — | — | $251.0M | $305.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EXEL // BETA 0.96
NBIX // BETA 1.13